1-3 of 3
Ainsley Ross
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Joseph P. McGuirk, Constantine S. Tam, Nicolaus Kröger, Peter A. Riedell, Hemant S. Murthy, Phoebe Joy Ho, Joseph E. Maakaron, Edmund K. Waller, Farrukh T. Awan, Paul J. Shaughnessy, Armin Ghobadi, Michael R. Bishop, Ana Alfonso-Pierola, Michael Dickinson, Praveen Ramakrishnan Geethakumari, Ainsley Ross, William Stevens, Huansheng Xu, Anna Ma, Sarah Beaussant Cohen, Richard T. Maziarz, Carlos Bachier
Journal: Blood
Blood (2022) 140 (Supplement 1): 10303–10306.
https://doi.org/10.1182/blood-2022-166432
Published: 2022
Journal Articles

Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A 2A receptor agonist regadenoson

Clinical Trials & Observations
Joshua J. Field, Gene Lin, Maureen M. Okam, Elaine Majerus, Jeffrey Keefer, Onyinye Onyekwere, Ainsley Ross, Federico Campigotto, Donna Neuberg, Joel Linden, David G. Nathan
Journal: Blood
Blood (2013) 121 (17): 3329–3334.
https://doi.org/10.1182/blood-2012-11-465963
Published: 2013
Includes: Supplemental data
Journal Articles

Regadenoson, An Adenosine 2A Receptor Agonist, Is Safe and Inhibits Invariant NKT Cells in Sickle Cell Disease

Joshua Field, MD, MS, Gene Lin, MD, PhD, Maureen Okam, MD, MPH, Elaine Majerus, MD, PhD, Onyinye Onyekwere, MD, MS, Ainsley Ross, BA, Donna Neuberg, ScD, Federico Campigotto, MS, David G. Nathan, MD, Joel Linden, PhD
Journal: Blood
Blood (2011) 118 (21): 849.
https://doi.org/10.1182/blood.V118.21.849.849
Published: 2011